IPAC Survey for PHSA employeesOct142015

WhatDoYouThinkPHSA’s Infection Prevention and Control (IPAC) team would like to hear what you think of the services they provide.  Their survey is open to all employees of the agencies they serve:

  • BC Women’s Hospital
  • BC Children’s Hospital and Sunny Hill
  • BC Cancer Agency (all centers)
  • BC Centre for Disease Control
  • BC Mental Health and Addictions
  • BC Emergency Health Services

The survey is completely anonymous, and takes about 5 minutes to complete. You could also win a Starbucks gift card! Please note: you must use Google Chrome, not Internet Explorer, to complete the survey. If you don’t have Chrome on your computer, you can contact the Service Desk.

Click here to take the survey

The survey is open from October 14-31, 2015. Prize winners will be contacted on November 4th.

More about the Infection Prevention and Control (IPAC) Perception Survey

What?  The IPAC team at PHSA needs your input in order to improve the quality of IPAC services delivered at the PHSA agencies they serve. The survey is completely anonymous.

Who?  Employees of the PHSA agencies listed above are invited to complete the survey:

When? The survey runs from October 14 -31, 2015.

Questions?  If you have questions about this survey, please contact Jun Collet, Infection Control Epidemiologist, PHSA IPAC services, at jccollet@cw.bc.ca or (604) 8752345 ext.7427.

The IPAC team is looking forward to hearing from you!


PICNet Co-Directors Lead Pilot StudyOct062015


Are self-disinfecting surfaces the “Midas” touch for reducing hospital infections? Pilot study examines environmental and genomic solution for healthcare associated infections

Healthcare associated infections (HAIs) are a major burden on patients and healthcare systems worldwide.  Despite strict hygiene practices and other preventative measures in hospitals there are an estimated 220,000 cases with 8,000 deaths per year in Canada. Costs associated with HAIs are estimated to be over $15 million per year for Vancouver Coastal Health (VCHA) alone. One of the highest risk groups for HAIs are Bone Marrow Transplant (BMT) patients.  These patients’ immune systems are weakened during the course of their treatment making them highly vulnerable to pathogens until their immune system recovers. 

Dr Elizabeth Bryce, Regional Medical Director for Infection Prevention and Control, Vancouver Coastal Health, Dr. Raewyn Broady, Director of the BMT program, and Dr. Linda Hoang, Medical Microbiologist, at the BC Public Health Lab, part of the BC Centre for Disease Control, are leading a two-year pilot study that will tackle reducing the risk of infection in BMT patients using two complimentary and novel approaches. First, to reduce the bio-burden on all touch surfaces, three patient isolation rooms will be re-engineered with self-disinfecting surfaces containing copper-nickel and titanium dioxide and outfitted with contact-free motion activated devices, filtered water, and ultraviolet light in the bathroom. Second, surveillance for pathogens in patients, healthcare workers and rooms will be addressed by microbiome profiling and the current standard of care microbial culturing.

The study leaders anticipate valuable insights into the role that the hospital environment (and healthcare staff) may have on the evolution of a BMT patient’s microbiome during the transplant and recovery process.  This in turn should provide ideas into improved methods to reduce HAIs for this target patient cohort as well as informing general infection prevention strategies.  Their hope is to gather enough evidence to establish a future large scale study across the country to reduce HAIs and ultimately decrease the morbidity and associated economic burden on healthcare spending.

“Infections cost patients and hospitals. By taking advantage of novel engineering along with advances in genomics, we hope to better understand the transmission dynamics of microbes between the patient, the healthcare worker and the environment,”  Says Dr. Bryce. “Clearer understanding of this relationship will allow us to better evaluate newer healthcare technologies and improve the effectiveness of infection prevention measures.”

Previous health economic evaluations on infection prevention and control programs at Vancouver Coastal Health demonstrated that improved strategies can lead to significant HAI reductions and millions of dollars in cost avoidance- increasing optimization of bed occupation, reduction in isolation cleaning, medications, and an increased returned time to nursing care.

“Incorporating microbiome surveillance into the multifaceted hospital environment including, patients, workers, and the rooms themselves provides a unique level of detail,” says Dr. Alan Winter, President and CEO of Genome BC. “We are pleased to be supporting a project that could prevent infection in some of the most susceptible patients in BC and beyond.”

This project, Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients is valued at approximately $400,000 and was funded by Genome BC’s User Partnership Program (UPP), the VGH & UBC Hospital Foundation and is also supported by the Public Health Agency of Canada. Project management and products have been donated through the Coalition Healthcare Acquired Infection Reduction (CHAIR) Canada.

For more information on the UPP program please click here

About Genome British Columbia:
Genome British Columbia is a catalyst for the life sciences cluster on Canada’s West Coast, and manages a cumulative portfolio of over $710M in 254 research projects and science and technology platforms. Working with governments, academia and industry across sectors such as forestry, fisheries and aquaculture, agri-food, energy and mining, environment, and human health, the goal of the organization is to generate social and economic benefits for British Columbia and Canada. Genome BC is supported by the Province of British Columbia, the Government of Canada through Genome Canada and Western Economic Diversification Canada and more than 300 international public and private co-funding partners. www.genomebc.ca


Nobel Prizes in MedicineOct052015

Three scientists from Ireland, Japan and China won the Nobel Prize in medicine on Monday for discovering drugs against malaria and other parasitic diseases that affect hundreds of millions of people every year. The Nobel judges in Stockholm awarded the prestigious prize to Irish-born William Campbell, Satoshi Omura of Japan and Tu Youyou — the first-ever Chinese medicine laureate.

Campbell and Omura were cited for discovering avermectin, derivatives of which have helped lower the incidence of river blindness and lymphatic filariasis, two diseases caused by parasitic worms that affect millions of people in Africa and Asia. Tu discovered artemisinin, a drug that has helped significantly reduce the mortality rates of malaria patients.

The Nobel committee said the winners, who are all in their 80s and made their breakthroughs in the 1970s and ‘80s, had given humankind powerful tools to combat debilitating diseases.

You can read the full article on the Globe and Mail website


Avian Influenza A(H7N9) Virus Infection in 2 Travelers Returning from China to Canada, January 2015Oct012015

In January 2015, the first two human infections due to avian influenza A(H7N9) were detected in North America, reported among two travelers returning from China to British Columbia, Canada.

The patients presented with typical influenza-like illness. They were detected in the outpatient setting through a series of somewhat fortuitous events – notably the collection of a specimen by the healthcare worker in response to travel history and the detection of a non-subtypeable influenza (despite high viral load) by the BC Public Health Microbiology and Reference Laboratory, that triggered further investigation.

There was no further spread but separate sero-survey showed broad population susceptibility to the novel H7N9 virus in British Columbia.

Case details, insights and lessons to be learned from these importations have recently been summarized in a Dispatch published last week in Emerging Infectious Diseases, available through open access e-publication, here: http://wwwnc.cdc.gov/eid/article/22/1/15-1330_article